USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

On its clinic website, the supermarket chain said the self-injectable pens can be used once a week to increase a user’s ...

Read the full paper here. The post Study finds erectile dysfunction for 1 in 5 men even years after Covid infection appeared first on Boing Boing.

A new study conducted on medical students found that those who suffer from Irritable Bowel Syndrome are 108 percent more likely to develop erectile dysfunction.

Postoperative penile hypoxia is one potential contributor, Pedersen and co-authors noted. The rationale for LI-SWT to treat ...

Of 609 men surveyed, 19% continued to have erectile dysfunction after being hospitalized with COVID-19. Nearly half still had ED after two years.

A recent research presented at the ENDO 2025 revealed that high blood sugar levels can impact men's sexual health. The ...

The health study found medications commonly prescribed for erectile dysfunction are associated with significant reductions in deaths, cardiovascular disease, and dementia ...

A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy).

New research highlights that 65.8% of diabetic men suffer from erectile dysfunction. Early detection and better diabetes control are key to reducing this common yet serious condition.

The study found that after 176 weeks, only 10 tirzepatide-treated patients progressed to diabetes, representing a roughly 93% reduction in risk compared to the placebo group. More than 90% of the ...